Data gathered: January 30
AI Stock Analysis - NovoCure (NVCR)
Analysis generated July 15, 2024. Powered by Chat GPT.
NovoCure Ltd. (NASDAQ: NVCR) is a global oncology company that develops and commercializes innovative therapeutic products for treating patients with cancer. The cornerstone of the company's technology is based on Tumor Treating Fields (TTFields), a unique therapeutic approach that utilizes electric fields to disrupt cancer cell division. Founded in 2000, NovoCure has been at the forefront of developing TTFields to offer non-invasive cancer treatment options. The company's flagship product, Optune, has shown efficacy in treating glioblastoma multiforme (GBM), particularly for patients with recurrent or newly diagnosed conditions.
Stock Alerts - NovoCure (NVCR)
 |
NovoCure | January 16 Insider Alert: Paravasthu Mukund is selling shares |
|
NovoCure | January 15 AI Score is up by 23.2% in the last couple of days. |
|
NovoCure | January 11 Over the past few months, there has been an upward trend in Web Traffic. |
|
NovoCure | January 10 Price is down by -5.1% in the last 24h. |
Alternative Data for NovoCure
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 46 | Sign up | Sign up | Sign up |
| Sentiment | 78 | Sign up | Sign up | Sign up |
| Webpage traffic | 52,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | 14 | Sign up | Sign up | Sign up |
| Patents | 195 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,467 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,727 | Sign up | Sign up | Sign up |
| Twitter Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 45 | Sign up | Sign up | Sign up |
| Business Outlook | 38 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,384 | Sign up | Sign up | Sign up |
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma.
| Price | $25.51 |
| Target Price | Sign up |
| Volume | 520,220 |
| Market Cap | $2.77B |
| Year Range | $14.54 - $33.41 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Earnings Date | February 27 '25 |
| Industry | Medical & Dental Instruments |
In the news
Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’January 30 - Yahoo Entertainment |
|
 |
NovoCure Limited (NASDAQ:NVCR) Given Average Rating of “Moderate Buy” by BrokeragesJanuary 29 - ETF Daily News |
|
FY2024 EPS Estimates for NovoCure Boosted by HC WainwrightJanuary 18 - ETF Daily News |
|
HC Wainwright Predicts NovoCure FY2029 EarningsJanuary 18 - ETF Daily News |
|
What is Wedbush’s Estimate for NovoCure FY2024 Earnings?January 17 - ETF Daily News |
 |
NovoCure (NASDAQ:NVCR) Receives “Neutral” Rating from WedbushJanuary 13 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 155M | 35M | 120M | -31M | -26M | -0.280 |
| Q2 '24 | 150M | 35M | 116M | -33M | -27M | -0.310 |
| Q1 '24 | 139M | 34M | 105M | -39M | -34M | -0.360 |
| Q4 '23 | 134M | 33M | 101M | -47M | -15M | -0.450 |
| Q3 '23 | 127M | 32M | 95M | -49M | -52M | -0.460 |
Insider Transactions View All
| Paravasthu Mukund filed to sell 31,437 shares at $26.8. January 15 '25 |
| Paravasthu Mukund filed to sell 3,459 shares at $16.7. November 6 '24 |
| Paravasthu Mukund filed to sell 3,503 shares at $15.9. November 4 '24 |
| Leonard Frank X filed to sell 161,236 shares at $15.9. November 4 '24 |
| Puri Michal Nath filed to sell 110,093 shares at $15.8. November 4 '24 |
Similar companies
Read more about NovoCure (NVCR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of NovoCure?
The Market Cap of NovoCure is $2.77B.
When does NovoCure report earnings?
NovoCure will report its next earnings on February 27 '25.
What is the current stock price of NovoCure?
Currently, the price of one share of NovoCure stock is $25.51.
How can I analyze the NVCR stock price chart for investment decisions?
The NVCR stock price chart above provides a comprehensive visual representation of NovoCure's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling NovoCure shares. Our platform offers an up-to-date NVCR stock price chart, along with technical data analysis and alternative data insights.
Does NVCR offer dividends to its shareholders?
As of our latest update, NovoCure (NVCR) does not offer dividends to its shareholders. Investors interested in NovoCure should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of NovoCure?
Some of the similar stocks of NovoCure are Align Technology, Dentsply, LeMaitre Vascular, iRhythm Technologies, and Silk Road Medical.
.